Last edition
News about Global Pharma
Australia-headquartered Novotech to acquire EastHORN
The acquisition is part of Novotech's global expansion programme
Global Pharma | 17/01/2023 | By Sudeep Soparkar
The lab will be a dedicated facility for integrated discovery work streams including medicinal and synthetic chemistry, in vitro biology, and process chemistry
Global Pharma | 11/01/2023 | By Sudeep Soparkar
PIRC will be equipped with a state-of-the-art lab featuring cutting-edge technology to support the identification and development of therapeutic opportunities
Global Pharma | 09/01/2023 | By Sudeep Soparkar
Polysciences creates new bioprocessing brand, Kyfora Bio
Based in Horsham, PA, Kyfora Bio will occupy a 45,000 sq ft cGMP facility with administrative offices, R&D labs, manufacturing suites
Global Pharma | 03/01/2023 | By Sudeep Soparkar
Global Pharma | 30/12/2022 | By Sudeep Soparkar
Advent International to pick up 50.1% in Suven Pharma for Rs 6,313 Cr
The buyout is part of the private equity firm’s plan to create a contract drug manufacturing powerhouse in India
Global Pharma | 27/12/2022 | By Sudeep Soparkar
KBI Biopharma secures Swissmedic Regulatory Establishment License for Geneva facility
The license allows KBI to fully support clients in their next phases of growth and certifies KBI's manufacturing capabilities in a cGMP environment
Global Pharma | 26/12/2022 | By Sudeep Soparkar
Florida-based Formulated Solutions to buy Merck & Co and Bayer manufacturing facility
The manufacturing facility is located in Cleveland, Tennessee
Global Pharma | 21/12/2022 | By Sudeep Soparkar | 199
JB Pharma to acquire the entire Razel (Rosuvastatin) franchise for Rs. 314 crores
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy. Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country <br />
Global Pharma | 15/12/2022 | By Sudeep Soparkar
Lupin appoints Spiro Gavaris as President of US generics biz
Gavaris will be responsible for the overall strategy, implementation and growth of Lupin’s US Generics business
Global Pharma | 09/12/2022 | By Sudeep Soparkar
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy